Until today, a variety of PARP1 inhibitor has been developed and clinically used for ovarian, breast and other carcinomas with promising efficiency, and furthermore, new inhibitors such as veliparib and talazoparib have been entered clinical trials [28]. The gene discussed is PARP1; the disease is carcinoma.